Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALXN2030 in Healthy Participants
NCT05501717Phase 1Active, not recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Aug 2022
- Primary completion
- Oct 2025
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ALXN2030 (6 arms), sponsored by Alexion Pharmaceuticals. Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs). Started Aug 2022; status: active, not recruiting.
02
Drugs
ALXN2030
Beyond the preview
Go deeper on NCT05501717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05501717.